Riga, Latvia

Jevgenijs Rozhkovs

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jevgenijs Rozhkovs: Innovator in Pharmaceutical Chemistry

Introduction

Jevgenijs Rozhkovs is a notable inventor based in Riga, Latvia. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target neurological disorders. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

Jevgenijs Rozhkovs holds a patent for a glycine B antagonist. This invention relates to quinoline derivatives and their pharmaceutically acceptable salts. The patent outlines a process for the preparation of these compounds, which are essential for controlling and preventing various disorders, including neurological conditions. His work in this area demonstrates a commitment to addressing critical health challenges.

Career Highlights

Currently, Jevgenijs Rozhkovs is employed at Merz Pharma GmbH & Co. KGaA, a company known for its focus on innovative healthcare solutions. His role at Merz Pharma allows him to apply his knowledge and skills in a collaborative environment, contributing to the development of effective treatments.

Collaborations

Throughout his career, Jevgenijs has worked alongside talented professionals such as Markus Henrich and Angela Bauer. These collaborations have enriched his research and development efforts, fostering an environment of innovation and shared knowledge.

Conclusion

Jevgenijs Rozhkovs is a distinguished inventor whose work in pharmaceutical chemistry has the potential to make a significant impact on the treatment of neurological disorders. His patent for glycine B antagonists exemplifies his innovative spirit and dedication to improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…